Weibo @ 国 投 集团 图
News Center of the State-owned Assets Supervision and Administration Commission of the State Council Bo April 28 news, on April 12, the world’s first recombinant new coronavirus vaccine jointly developed by Academician Chen Wei of the Academy of Military Medical Sciences and the National Investment Group’s innovative investment company Kangxin Bio entered the second phase of clinical trials. On the 27th, Kangxinuo Bio issued an announcement that the company had submitted a request for a pre-application meeting of a recombinant new coronavirus vaccine (adenoviral vector) clinical trial to Health Canada on April 24, 2020. Health Canada accepted the clinical trial application Meeting request. Academician Chen Wei revealed that at present, 508 volunteers of the second clinical trial of recombinant adenovirus vector recombinant coronavirus vaccine have been injected and are now in the observation period. If all goes well, they will be blinded in May this year.
(Originally titled “International Cooperation, Anti-epidemic Science and Technology! Health Canada Accepts Requests for Pre-Meeting Applications for Clinical Trials of Recombinant New Crown Vaccine”)